Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | CDC25A | P30304 | 1/20 | 0.56 |
| ▸ | CDC25C | P30307 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 5/20 | 0.51 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2150990 | 0.89 | PARP1 (0.64) | PGRKDM4ECDC25ACDC25CALDH1A1 | |
| SCHEMBL4095791 | 0.81 | ACHE (0.69) | PGRKDM4EKIF11PARP1DAO | |
| SCHEMBL29387074 | 0.80 | ACHE (0.67) | KDM4ECDC25ACDC25CALDH1A1KIF11 | |
| SCHEMBL15379639 | 0.80 | ACHE (0.67) | KDM4ECDC25ACDC25CALDH1A1KIF11 | |
| SCHEMBL1383605 | 0.80 | CA12 (0.54) | PGRKDM4ECDC25ACDC25CALDH1A1 | |
| SCHEMBL8873789 | 0.78 | KDM4E (0.67) | PGRKDM4ECDC25ACDC25CALDH1A1 | |
| SCHEMBL15380304 | 0.77 | KIF11 (0.75) | KDM4ECDC25ACDC25CALDH1A1KIF11 | |
| SCHEMBL7123791 | 0.77 | KEAP1 (0.54) | PGRKDM4ECDC25ACDC25CALDH1A1 | |
| SCHEMBL20227580 | 0.76 | PARP1 (0.67) | KDM4ECDC25ACDC25CGAAPARP1 | |
| SCHEMBL3422670 | 0.76 | KDM4E (0.53) | PGRKDM4ECDC25ACDC25CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2805726-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2468285-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2014-10-15 | — | — | EP | disclosed |
| CN-103896950-A | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENATA PHARMACEUTICALS INC | 2014-07-02 | — | — | CN | disclosed |
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| CN-101775017-B | Macrocyclic hepatitis c serine protease inhibitors | ABBOTT LAB | 2014-04-30 | — | — | CN | disclosed |
| EP-2468287-B1 | Macrocyclic hepatitis c serine protease inhibitors | ENANTA PHARM INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2340029-B1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8642538-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| CN-102641271-B | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARJMACEUTICALS INC | 2013-12-25 | — | — | CN | disclosed |
| US-8420596-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120196792-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2468285-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468287-A1 | Macrocyclic hepatitis c serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2340029-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2010030359-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARJMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | PGR 1606/4885KDM4E 2948/4885CDC25A 1208/4885 |
| US-20120196792-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | PGR 1606/4885KDM4E 2948/4885CDC25A 1208/4885 |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | TMPRSS15, PRSS1, SPINT2 | PGR 1606/4885KDM4E 2948/4885CDC25A 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.